Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
You must be a Standard 1 Year member to access this content.
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
You must be a Standard 1 Year member to access this content.
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its Series C financing, which totaled over $300 million. Tessera is a biotechnology company pioneering a...
You must be a Standard 1 Year member to access this content.
Goodwin advised Tessera Therapeutics on the deal. Tessera Therapeutics announced its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Maples and Calder represented Social Capital Suvretta Holdings Corp. I in the transaction. Goodwin Procter advised Akili, while Skadden, Arps,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised CardioFocus, Inc. on the deal. CardioFocus, Inc. announced its licensing and distribution agreement with China Grand Pharmaceutical (Grand Pharma). The agreement provides a license...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Minovia Therapeutics on the deal. Minovia Therapeutics announced its worldwide strategic collaboration and license agreement with Astellas Pharma (TSE: 4503) to research, develop, and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Cerevel Therapeutics on the deal. Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Akili Interactive on the deal. Akili Interactive announced its $160 million in combined equity and debt financing. Akili is the maker of EndeavorRx™,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
You must be a Standard 1 Year member to access this content.
